Table 4.

Factors associated with progression-free survival in patient with FIGO stage III to IV disease according to primary treatment strategy

Characteristic		Primary debulking surgery						Neoadjuvant chemotherapy
		Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
		HR	95% CI	p-value	aHR	95% CI	p-value	HR	95% CI	p-value	aHR	95% CI	p-value
Age (yr)
	< 55	1			1			1			1
	≥ 55	1.286	0.952-1.737	0.101	1.491	1.060-2.097	0.022	1.543	1.020-2.333	0.040	1.508	0.948-2.401	0.083
FIGO stage
	III	1			1			1			1
	IV	1.587	1.107-2.275	0.012	1.873	1.263-2.777	0.002	0.895	0.604-1.327	0.581	0.691	0.439-1.088	0.111
Histology
	High-grade serous	1			1			1			1
	Non–high-grade serous	1.203	0.815-1.775	0.352	1.658	1.085-2.533	0.019	0.856	0.423-1.736	0.667	1.076	0.458-2.529	0.866
Initial serum CA-125 (IU/mL)
	< 900	1			1			1			1
	≥ 900	1.201	0.871-1.658	0.264	1.189	0.848-1.668	0.316	1.219	0.787-1.889	0.374	1.256	0.786-2.007	0.341
Residual tumor after PDS/IDS
	< 1 cm	1			1			1			1
	≥ 1 cm	1.471	0.975-2.218	0.066	1.340	0.857-2.096	0.200	1.887	0.943-3.775	0.073	3.200	1.357-7.544	0.008
BRCA mutational status
	Wild-type	1			1			1			1
	Mutation	0.940	0.682-1.295	0.705	0.759	0.530-1.089	0.135	0.659	0.431-1.008	0.054	0.619	0.385-0.995	0.048

FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; CA-125, cancer antigen 125; PDS, primary debulking surgery; IDS, interval debulking surgery.